Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.

समान संसाधन

• Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
  द्वारा: Satoshi Kawano, और अन्य
  प्रकाशित: (2016-01-01)
• Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas.
  द्वारा: Sarah K Knutson, और अन्य
  प्रकाशित: (2014-01-01)
• EZH2 inhibition sensitizes retinoic acid-driven senescence in synovial sarcoma
  द्वारा: Muhammad Mushtaq, और अन्य
  प्रकाशित: (2024-11-01)
• Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2)
  द्वारा: Changchien Yi-Che, और अन्य
  प्रकाशित: (2012-10-01)
• Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors
  द्वारा: Haruka Shinohara, और अन्य
  प्रकाशित: (2022-12-01)